首页 | 本学科首页   官方微博 | 高级检索  
检索        


Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines
Institution:1. Vaccines Medical Development & Scientific Affairs, Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA;2. JMI Laboratories, North Liberty, IA, USA;3. Vaccines Medical Development & Scientific Affairs, Pfizer Inc, Collegeville, PA, USA;4. Vaccines Medical Development & Scientific Affairs, Pfizer Inc, Paris, France
Abstract:BackgroundSouth Korea has been providing 10-valent pneumococcal conjugate vaccine/(PCV10)/13-valent pneumococcal conjugate vaccine (PCV13) to children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to older adults as part of a national immunization program.MethodsFrom September 2015 to August 2017, a prospective cohort study was conducted for adults aged ≥19 years with community-acquired pneumonia (CAP) at four university hospitals. All-cause and pneumococcal CAP incidence and mortality rates were evaluated on the basis of hospital catchment population. Serotype distribution of pneumococcal CAP was also evaluated.ResultsAmong 2669 patients with CAP, 252 cases (9.4%) were pneumococcal CAP cases. The annual incidences of all-cause and pneumococcal CAP were 194.3 cases and 18.3 cases respectively, per 100,000 persons. Serotyped Streptococcus pneumoniae was identified in 107 cases (42.5%) through culture or a serotype-specific urinary antigen detection assay. Pneumococcal CAP caused by the PCV13 and PPSV23 serotypes were 50 cases (46.7% of serotyped pneumococcal CAP and 19.8% of pneumococcal CAP), and 83 cases (77.6% of serotyped pneumococcal CAP and 32.9% of pneumococcal CAP), respectively. The most prevalent serotype was 3 (n = 21, 19.6% of serotyped pneumococcal CAP), followed by 19A (n = 10, 9.3% of serotyped pneumococcal CAP) and 11A (n = 10, 9.3% of serotyped pneumococcal CAP). Compared with non-pneumococcal CAP patients, pneumococcal CAP patients were more likely to have a higher CURB-65 scores (P = 0.002). The overall 30-day mortality rate of pneumococcal CAP was higher than that of non-pneumococcal CAP (6.3% versus 5.6%; odds ratio OR], 1.15; 95% confidence interval CI], 0.67–1.96), but this trend was reversed in patients aged 65–74 years (4.2% versus 8.6%; OR, 0.47; 95% CI, 0.14–1.54).ConclusionsThe disease burden of PCV13-serotype pneumococcal CAP remains significantly high in Korean adults, particularly among elderly people, even after a high uptake of pediatric PCVs.
Keywords:Community-acquired pneumonia  Pneumococcus  Incidence  Mortality  Epidemiology  PCV10"}  {"#name":"keyword"  "$":{"id":"k0035"}  "$$":[{"#name":"text"  "_":"10-valent pneumococcal conjugate vaccine  PCV13"}  {"#name":"keyword"  "$":{"id":"k0045"}  "$$":[{"#name":"text"  "_":"13-valent pneumococcal conjugate vaccine  PPSV23"}  {"#name":"keyword"  "$":{"id":"k0055"}  "$$":[{"#name":"text"  "_":"23-valent pneumococcal polysaccharide vaccine  CAP"}  {"#name":"keyword"  "$":{"id":"k0065"}  "$$":[{"#name":"text"  "_":"Community-acquired pneumonia  CURB"}  {"#name":"keyword"  "$":{"id":"k0075"}  "$$":[{"#name":"text"  "_":"Confusion  urea  respiratory rate and blood pressure  IPDs"}  {"#name":"keyword"  "$":{"id":"k0085"}  "$$":[{"#name":"text"  "_":"Invasive pneumococcal diseases  PCV7"}  {"#name":"keyword"  "$":{"id":"k0095"}  "$$":[{"#name":"text"  "_":"7-valent pneumococcal conjugate vaccine  HAP"}  {"#name":"keyword"  "$":{"id":"k0105"}  "$$":[{"#name":"text"  "_":"Hospital-acquired pneumonia  UAD"}  {"#name":"keyword"  "$":{"id":"k0115"}  "$$":[{"#name":"text"  "_":"Urinary antigen detection  ssUAD"}  {"#name":"keyword"  "$":{"id":"k0125"}  "$$":[{"#name":"text"  "_":"Serotype-specific UAD  BAL"}  {"#name":"keyword"  "$":{"id":"k0135"}  "$$":[{"#name":"text"  "_":"Broncho-alveolar lavage  WBCs"}  {"#name":"keyword"  "$":{"id":"k0145"}  "$$":[{"#name":"text"  "_":"White blood cells  HIV"}  {"#name":"keyword"  "$":{"id":"k0155"}  "$$":[{"#name":"text"  "_":"Human immunodeficiency virus  KOSIS"}  {"#name":"keyword"  "$":{"id":"k0165"}  "$$":[{"#name":"text"  "_":"Korean Statistical Information Service  OR"}  {"#name":"keyword"  "$":{"id":"k0175"}  "$$":[{"#name":"text"  "_":"Odds ratio  NIP"}  {"#name":"keyword"  "$":{"id":"k0185"}  "$$":[{"#name":"text"  "_":"National Immunization Program  HIRA"}  {"#name":"keyword"  "$":{"id":"k0195"}  "$$":[{"#name":"text"  "_":"Health Insurance and Review Assessment  US"}  {"#name":"keyword"  "$":{"id":"k0205"}  "$$":[{"#name":"text"  "_":"United States  UK"}  {"#name":"keyword"  "$":{"id":"k0215"}  "$$":[{"#name":"text"  "_":"United Kingdom  CI"}  {"#name":"keyword"  "$":{"id":"k0225"}  "$$":[{"#name":"text"  "_":"Confidence interval
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号